Ind-Swift Laboratories Posts Strong Q1 FY27 Results; Operating EBITDA Rises 2.85x YoY
Ind-Swift Laboratories Limited, a global pharmaceutical formulations company operating in over 85 countries, has reported robust un-audited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27). The company demonstrated significant growth in profitability and margins while strengthening its position as a debt-free formulations platform.The Q1 performance saw substantial improvements across key metrics. Operating Income grew by 21.16%, with operating EBITDA increasing by 2.85x year-over-year (YoY). Concurrently, the operating EBITDA margin expanded significantly, reaching 17.91%. Net Profit After Tax (PAT), excluding exceptional...